Takashima Tetsuya, Danno Katsura, Tamura Yoshitaka, Nagai Takayuki, Matsumoto Tomoshige, Han Yuki, Ano Hiromi, Yoshida Hiroko, Kawahara Kunimitsu, Tsuyuguchi Izuo
Department of Tuberculosis Medicine, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1, Habikino, Habikino-shi, Osaka 583-8588, Japan.
Kekkaku. 2006 Jun;81(6):413-8.
To know the treatment outcome of patients with multidrug-resistant tuberculosis (MDR-TB) during gestation.
Retrospective study of 3 cases of pregnant women, who were treated for MDR-TB with a regimen including pyrazinamide, ethambutol, para-aminosalicylic acid, cycloserine and amoxicillin-clavulanic acid.
All patients showed a good response to anti-tuberculosis chemotherapy without any serious adverse effect, and were culture-negative at the time of delivery. Two patients delivered vaginally at weeks 40, and one patient delivered surgically at weeks 38. All newborns were healthy, and their tuberculin skin tests and placental tissue examinations were negative for tuberculosis.
MDR-TB can be successfully treated during pregnancy by using a regimen including effective second-line anti-tuberculosis drugs.
了解妊娠期耐多药结核病（MDR-TB）患者的治疗结局。
对3例孕妇进行回顾性研究，她们接受了包含吡嗪酰胺、乙胺丁醇、对氨基水杨酸、环丝氨酸和阿莫西林-克拉维酸的方案治疗耐多药结核病。
所有患者对抗结核化疗均有良好反应，无任何严重不良反应，分娩时痰培养均为阴性。2例患者在40周时经阴道分娩，1例患者在38周时接受剖宫产。所有新生儿均健康，其结核菌素皮肤试验和胎盘组织检查均未发现结核病。
使用包含有效二线抗结核药物的方案，妊娠期耐多药结核病可得到成功治疗。
